211 related articles for article (PubMed ID: 33691276)
1. Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry.
Blunt DN; Smyth L; Nagamuthu C; Gatov E; Croxford R; Mozessohn L; Cheung MC
J Natl Compr Canc Netw; 2021 Mar; 19(6):719-725. PubMed ID: 33691276
[TBL] [Abstract][Full Text] [Related]
2. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
Smyth L; Blunt DN; Gatov E; Nagamuthu C; Croxford R; Mozessohn L; Cheung MC
Br J Haematol; 2020 Nov; 191(3):396-404. PubMed ID: 32304100
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
4. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
5. The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.
Arya S; Mozessohn L; Gong I; Faught N; Liu N; Singh S; Chan K; Cheung MC
Leuk Lymphoma; 2024 May; 65(5):629-637. PubMed ID: 38265355
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
7. Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study.
Gong IY; Cheung MC; Chan KKW; Arya S; Faught N; Calzavara A; Liu N; Odejide OO; Abel G; Kurdyak P; Raphael MJ; Kuczmarski T; Prica A; Mozessohn L
J Natl Cancer Inst; 2023 Oct; 115(10):1194-1203. PubMed ID: 37531271
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Maurer MJ; Habermann TM; Shi Q; Schmitz N; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Flowers CR; Coiffier B
Ann Oncol; 2018 Aug; 29(8):1822-1827. PubMed ID: 29897404
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
12. Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP.
Wang J; Zhou M; Wang X; Xu J; Chen B; Ouyang J
Clin Chim Acta; 2016 Aug; 459():150-154. PubMed ID: 27262822
[TBL] [Abstract][Full Text] [Related]
13. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
[TBL] [Abstract][Full Text] [Related]
15. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
[TBL] [Abstract][Full Text] [Related]
16. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
17. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ; Ghesquières H; Link BK; Jais JP; Habermann TM; Thompson CA; Haioun C; Allmer C; Johnston PB; Delarue R; Micallef IN; Peyrade F; Inwards DJ; Ketterer N; Farooq U; Fitoussi O; Macon WR; Molina TJ; Syrbu S; Feldman AL; Slager SL; Weiner GJ; Ansell SM; Cerhan JR; Salles GA; Witzig TE; Tilly H; Nowakowski GS
J Clin Oncol; 2018 Jun; 36(16):1603-1610. PubMed ID: 29672223
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
19. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
[No Abstract] [Full Text] [Related]
20. Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma.
Yoshida M; Nakaya Y; Shimizu K; Tatsumi N; Tsutsumi M; Fuseya H; Horiuchi M; Yoshimura T; Hayashi Y; Nakao T; Inoue T; Yamane T
Sci Rep; 2021 Feb; 11(1):2837. PubMed ID: 33531642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
